|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial显示文摘AIM To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of nonalcoholic steatohepatitis(NASH).METHODS Twelve patients with biopsy-proven NASH were randomized to sitagliptin(100 mg daily)(n=6)or placebo(n=6)for 24 wk.The primary outcome was improvement in liver fibrosis after 24 wk.Secondary outcomes included evaluation of changes in NAFLD activity score(NAS),individual components of NAS(hepatocyte ballooning,lobular inflammation,and steatosis),glycemic control and insulin resistance[including measurements of glycated hemoglobin(Hb A1C)and adipocytokines],lipid profile including free fatty acids,adipose distribution measured using magnetic resonance imaging(MRI),and thrombosis markers(platelet aggregation and plasminogen activator inhibitor 1 levels).We also sought to determine the correlation between changes in hepatic fat fraction(%)[as measured using the Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation(IDEAL)MRI technique]and changes in hepatic steatosis on liver biopsy.RESULTS Sitagliptin was not significantly better than placebo at reducing liver fibrosis score as measured on liver biopsy(mean difference between sitagliptin and placebo arms,0.40,P=0.82).There were no significant improvements evident with the use of sitagliptin vs placebo for the secondary histologic outcomes of NAS total score as well as for the individual components of NAS.Compared to baseline,those patients who received sitagliptin demonstrated improved Hb A1C(6.7%±0.4%vs 7.9%±1.0%,P=0.02),and trended towards improved adiponectin levels(4.7±3.5μg/m L vs 3.9±2.7μg/m L,P=0.06)and triglyceride levels(1.26±0.43 mmol/L vs 2.80±1.64 mmol/L,P=0.08).However,when compared with placebo,sitagliptin did not cause a statistically significant improvement in Hb A1C(mean difference,-0.7%,P=0.19)nor triglyceride levels(mean difference-1.10mmol/L,P=0.19)but did trend towards improved adiponectin levels only(mean difference,0.60μg/m L,P=0.095).No significant changes in anthropometrics,liver enzymes,other adipocytokines,lipid profile,thrombosis parameters,or adipose distribution were demonstrated.The MRI IDEAL procedure correlated well with steatosis scores obtained on liver biopsy in both groups at baseline and post-treatment,and the Spearman correlation coefficients ranged from r=0.819(baseline)to r=0.878(post-treatment),P=0.002.CONCLUSION Sitagliptin does not improve fibrosis score or NAS after 24 wk of therapy.The MRI IDEAL technique may be useful for non-invasive measurement of hepatic steatosis. | Tisha R Joy Charles A McKenzie Rommel G Tirona Kelly Summers Shannon Seney Subrata Chakrabarti Neel Malhotra Melanie D Beaton | 2017 | World Journal of Gastroenterology2017，23，1： | 18 |
| 2 | Digital fluoroscopy to quantify lung tumor motion:potential for patient-specific planning target volumes显示文摘 | Sixel KE Ruschin M Tirona R | 2003 | Int J Radiat Oncol Biol Phys2003，57，3： | 1 |
| 3 | Breast cancer resistance protein (ABCG2) and drug dispo- sition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe显示文摘 | Urquhart BL Ware JA Tirona RG | 2008 | Pharmacogenet Genomics2008，18，5： | 1 |
| 4 | Reproducibility of lung tumor position and reduction of lung mass within the planning target volume using active breathing control(ABC)显示文摘 | Cheung P C Sixel K E Tirona R | 2003 | Int J Radiat Oncol Biol Phys2003，57，5： | 1 |
| 5 | Use of CT simula- tion for treatment of cervical cancer to assess the adequacy of lymph node corverage of conventional pelvic dields based on bony land-marks显示文摘 | Finlay M H Ackerman I Tirona R G | 2006 | Int J Radiat Oncol Biol Phys2006，64，： | 1 |
| 6 | The orphan nuclear receptor HNF4alpha determines PXR-and CAR-mediated xenobiotic induction of CYP3A4显示文摘 | Tirona R G Lee W Leake B F | 2003 | Nat Med2003，9，2： | 1 |
| 7 | Drug and bile acid transporters inrosuvastatin hepatic uptake:function,expression,and pharmacogenetics显示文摘 | Ho RH Tirona RG Leake BF | 2006 | Gastroenterology2006，130，： | 1 |
| 8 | Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy显示文摘 | GONG IY TIRONA RG SCHWARZ UI | 2011 | Blood2011，118，11： | 1 |
| 9 | Molecular mechanisms of drug trans-porter regulation显示文摘 | Tirona RG | 2011 | Handb Exp Pharmacol2011，，201： | 1 |
| 10 | Correlation of lung tumor motion with external surrogate indicators of resp- iration显示文摘 | Hoisak J D Sixel K E Tirona R | 2004 | Int J Radiat Oncol Biol Phys2004，60，4： | 1 |
| 11 | Nuclear receptors and drug disposition gene regulation显示文摘 | Tirona RG Kim RB | 2005 | J Pharm Sci2005，94，6： | 1 |
| 12 | Reproducibility of lung tumor position and reduction of lung mass within the planning target volume using active breathing control (ABC)显示文摘 | Cheung PC Sixel KE Tirona R | 2003 | Int J Radiat Oncol Phys2003，57，5： | 1 |
| 13 | Nuclear receptors and drug disposition gene regulation显示文摘 | Tirona R G Kim R B | 2005 | Journal of Pharmaceutical Sciences2005，94，6： | 1 |
| 14 | Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe显示文摘 | Bradley L. Urquhart Joseph A. Ware Rommel G. Tirona Richard H. Ho Brenda F. Leake Ute I. Schwarz Hani Zaher Joe Palandra Jamie C. Gregor George K. Dresser Richard B. Kim | 2008 | Pharmacogenetics and Genomics2008，，5： | 1 |
| 15 | Breast cancer resistance protein (ABCG2) and drug disposition : intestinal expression, polymorphisms and sulfasalasine as an in vivo probe 显示文摘 | URQUHART BL WARE JA TIRONA RG | 2008 | Pharmacogenet Genomics2008，18，5： | 1 |
| 16 | Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter poly- peptide 1A2 selectively enhances estrogen effects in breast cancer显示文摘 | Meyer zu Schwabedissen HE Tirona RG Yip CS | 2008 | Cancer Res2008，68，22： | 1 |
| 17 | Use of CT simulation for treatment of cervical cancer to assess the adequacy of lymph node coverage of conventional pelvic fields based on bony landmarks显示文摘 | Finlay MH Ackerman I Tirona RG | 2006 | Int J Radiat Oncol Biol Phys2006，64，1： | 1 |
| 18 | Identification of novel functional organic anion-transporting polypeptide lb3 polymorphisms and assessment of substrate specificity 显示文摘 | Schwarz UI Meyer zu Schwabedissen HE Tirona RG | 2011 | Pharmacogenet Genomics2011，21，3： | 1 |
| 19 | A Common polymorphism in the bile acid receptor farnesoid x receptor is associated with decreased hepatic target gene expression 显示文摘 | Marzolini C Tirona RG Gervasini G | 2007 | Endocrinol2007，21，8： | 1 |
| 20 | Reproducibility of Lung tumor position and reduction of Lung mass within the planning target volume using active breathing control(ABC)显示文摘 | sixel KE Tirona R | 2003 | Int J Radiat Oncol Biol Phys2003，57，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员